Clinical trials: Topotecan
Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer
A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer) is a Phase 3 study during which patients with recurrent or persistent low-grade serous (LGS) carcinomas of the ovary, fallopian tube or primary peritoneum will…
- Conditions
- Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer, Low-grade Serous Peritoneal Cancer
- Trial name
- NCT01849874
- Testing
- MEK162, MEK inhibitor; oral, Physician's choice chemotherapy
- Where
- 226 sites in United States, Australia and 17 more
- Volunteers
- 341 people
- Sponsor
- Pfizer
Platinum-resistant Ovarian Cancer, Platinum-resistant Primary Peritoneal Cancer
A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
This is a randomized, open-label, multicenter Phase III clinical study designed to evaluate the efficacy and safety of SYS6043 versus investigator's choice chemotherapy in participants with platinum-resistant ovarian cancer…
- Conditions
- Platinum-resistant Ovarian Cancer, Platinum-resistant Primary Peritoneal Cancer, Platinum-resistant Fallopian Tube Cancer
- Trial name
- NCT07708753
- Testing
- SYS6043, Liposomal doxorubicin, paclitaxel, or topotecan
- Where
- China
- Volunteers
- 460 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Relapsed Small Cell Lung Cancer
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of Lurbinectedin monotherapy or Lurbinectedin + Irinotecan combined…
- Trial name
- NCT06496048
- Testing
- Lurbinectedin, Irinotecan, Topotecan
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Luye Pharma Group Ltd.
Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer)
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
This is a Phase Ib/II clinical study. The Phase Ib dose-escalation study aims to evaluate and determine the recommended Phase II dose (RP2D) of TCC1727 in combination with benmelstobart /olaparib /topotecanfor patients with…
- Conditions
- Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), Gastric (Stomach) Cancer, Endometrial Cancer
- Trial name
- NCT07371663
- Testing
- TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg
- Where
- 3 sites in China
- Volunteers
- 266 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Advanced Cancer, Metastatic Cervical Cancer
Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
This Phase 3 trial is an open-label, randomized study with single-agent Balstilimab (BAL) or Investigator Choice (IC) chemotherapy (single-agent gemcitabine, irinotecan, pemetrexed, vinorelbine, or topotecan) in patients with…
- Trial name
- NCT04943627
- Testing
- Balstilimab (BAL), Topotecan, Vinorelbine
- Where
- 3 sites in United States, Armenia
- Sponsor
- Agenus Inc.
Neoplasms, Ovarian
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator's choice (IC) chemotherapy in female participants with platinum-resistant HGS…
- Trial name
- NCT05613088
- Testing
- MORAb-202, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD)
- Where
- 50 sites in United States, Australia and 7 more
- Volunteers
- 106 people
- Sponsor
- Bristol-Myers Squibb
Lung Cancer, Small Cell
Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer
The purpose of this study is to find out if giving oral HYCAMTIN to patients with relapsed small cell lung cancer benefits them.
- Trial name
- NCT00276276
- Testing
- topotecan
- Where
- 17 sites in Bulgaria, Hungary and 4 more
- Volunteers
- 141 people
- Sponsor
- GlaxoSmithKline
Small Cell Lung Cancer (SCLC)
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).
- Trial name
- DeLLphi-304 (NCT05740566)
- Testing
- Tarlatamab, Lurbinectedin, Topotecan
- Where
- 223 sites in United States, Argentina and 29 more
- Volunteers
- 509 people
- Sponsor
- Amgen
Small Cell Lung Cancer
Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer
Primary Objective: To demonstrate progression free survival (PFS) improvement for cabazitaxel compared to topotecan in participants with sensitive or resistant/refractory small cell lung cancer following a first line platinum…
- Trial name
- NCT01500720
- Testing
- Cabazitaxel, Topotecan
- Where
- 58 sites in United States, Brazil and 14 more
- Volunteers
- 179 people
- Sponsor
- Sanofi
Lung Cancer, Small Cell
SCOT Registry: Small Cell Lung Cancer Treatment and Outcome
The registry is an international, multicenter, observational registry of newly diagnosed patients with SCLC. Data will be entered into an electronic CRF (eCRF) via Internet access.
- Trial name
- SCOT (NCT00997061)
- Testing
- HYCAMTIN
- Where
- 61 sites in Austria, Czechia and 12 more
- Volunteers
- 500 people
- Sponsor
- GlaxoSmithKline
Peritoneal Cancer, Ovarian Cancer
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
This research study was designed to determine the effectiveness of the drug, topotecan, given intravenously (into a vein) together with the drug gemcitabine in patients with recurrent platinum-sensitive ovarian, fallopian or…
- Conditions
- Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer
- Trial name
- NCT00061308
- Testing
- Topotecan, Gemcitabine
- Where
- 19 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- GlaxoSmithKline
Ovarian Cancer
Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer
The objective of this study is to assess the safety and efficacy of karenitecin versus topotecan in patients with platinum/taxane-resistant advanced epithelial ovarian cancer.
- Trial name
- NCT00477282
- Testing
- Karenitecin, Topotecan
- Where
- 48 sites in Hungary, Lithuania and 3 more
- Volunteers
- 509 people
- Sponsor
- BioNumerik Pharmaceuticals, Inc.
Malignant Solid Tumors
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan
The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with topotecan chemotherapy in patients with advanced solid tumours
- Trial name
- NCT00516438
- Testing
- KU-0059436 (AZD2281)(PARP inhibitor), Topotecan
- Where
- 3 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- AstraZeneca
Neoplasms, Endometrial, Endometrial Cancer
Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer
The purpose of this study is to find out if Hycamtin given weekly is safe and effective for treating your endometrial cancer.
- Trial name
- NCT00267488
- Testing
- topotecan
- Where
- 24 sites in United States, Canada and 1 more
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Small Cell Lung Cancer
A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer
This study was designed to compare the efficacy and safety of IBB0979 in combination with topotecan versus topotecan in subjects with relapsed small cell lung cancer (SCLC).
- Trial name
- NCT07076095
- Testing
- IBB0979, topotecan hydrochloride for injection
- Volunteers
- 200 people
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer
Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
The purpose of this clinical study is to confirm the utility of chemosensitivity (ChemoID) tumor testing on cancer stem cells as a predictor of clinical response in recurrent platinum resistant epithelial ovarian cancer (EOC)…
- Trial name
- NCT03949283
- Testing
- ChemoID Assay, Standard Chemotherapy
- Where
- 8 sites in United States
- Volunteers
- 150 people
- Sponsor
- Cordgenics, LLC
Non Small Cell Lung Cancer, Small-cell Lung Cancer
A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)
This is a Phase 1b, multicenter, 2-part study of ALRN-6924 for the prevention of chemotherapy-induced side effects. Part 1 SCLC is an open-label, multicenter study of ALRN-6924 for the prevention of chemotherapy-induced side…
- Trial name
- NCT04022876
- Testing
- ALRN-6924, Carboplatin, Pemetrexed
- Where
- 28 sites in United States, Bosnia and Herzegovina and 5 more
- Volunteers
- 35 people
- Sponsor
- Aileron Therapeutics, Inc.
Ovarian Cancer
Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate the activity and safety of PM01183 versus PLD or topotecan as control arm in patients with platinum-resistant ovarian cancer.
- Trial name
- CORAIL (NCT02421588)
- Testing
- Lurbinectedin (PM01183), Pegylated liposomal doxorubicin (PLD), Topotecan
- Where
- 28 sites in United States
- Volunteers
- 442 people
- Sponsor
- PharmaMar
Small Cell Lung Cancer
Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.
The purpose of the study is to evaluate the objective tumor response rate of amrubicin or standard topotecan therapy when administered as second-line therapy to ED-SCLC patients who have chemotherapy sensitive recurrent or…
- Trial name
- NCT00319969
- Testing
- Amrubicin, Topotecan
- Where
- 47 sites in United States
- Volunteers
- 76 people
- Sponsor
- Celgene Corporation
Small Cell Lung Cancer
A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of Belotecan administered 5 days every 3 weeks in comparison to Topotecan in Patients with relapsed small cell lung cancer.
- Trial name
- NCT01497873
- Testing
- Topotecan, Belotecan
- Where
- 14 sites in South Korea
- Volunteers
- 164 people
- Sponsor
- Chong Kun Dang Pharmaceutical